Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
(St. Jude Reference #)
|Neuropiln 1 (Nrp1) Modulation for Immune System (SJ-13-0012)|
|Description||Boosting the ability of regulatory T cells by blocking an effective anti-tumor immune response led to the elimination or dramatic reduction of melanoma by the immune system in mice, without causing the autoimmune and inflammatory problems often associated with current cancer-treatment efforts that target immune regulators. The mechanism is built around two proteins. One, semaphorin-4a (Sema4a), is carried on the surface of various immune cells that can spark inflammation. The other, neuropilin-1 (Nrp1), is carried on the surface of regulatory T cells. For a full press release about this technology, visit http://www.stjude.org/vignali-tregs|
|Keywords||Regulatory T cell (Treg), Neuropiln 1 (Nrp1), Semaphorin-4a (Sema4a), tumor-induced tolerance, tumor resistance, autoimmune, inflammation, cancer, immunotherapeutic|
|Granted Patents or Published Applications|
|Related Scientific References||'Regulatory T cell stability is maintained by a neuropilin-1:semaphorin-4a axis' is published on Nature.com: http://dx.doi.org/10.1038/nature12428. (Abstracts are available to everyone, full text only to subscribers; relevant references are cited in the paper and can be provided on request).|
|Licensing Opportunities||We are currently seeking nonexclusive licensing opportunities in all fields for the development of this technology.|
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.
Last update: August 2013
or browse our technology